News

nference Enters Long-Term Partnership with Cedars-Sinai to Develop AI-Enabled Platform for Advancing Clinical Research and Patient Care

The collaboration will establish a secure AI-enabled platform to help Cedars-Sinai investigators analyze de-identified, multimodal clinical data from over 5 million patients.

Making Headlines in Healthcare Innovation

PR Newswire
TIME
Reuters
NBC News
Endpoint News
Medpage Today
Avadel Pharmaceuticals plc
Business Wire
nference Portfolio Company
Becker's Hospital Review
Outsourcing Pharma
Becker's Health IT
The Pharma Letter
Fierce Healthcare
CBS News
nference & Mayo Clinic
STAT News
Mayo Clinic
Medical Design & Outscourcing
JAMA Network
USA Today
Axios
Fast Company
Healthcare Executive
Forbes
FierceBiotech
The Washington Post
The New York Times
PR Newswire
TIME
Reuters
NBC News
Endpoint News
Medpage Today
Avadel Pharmaceuticals plc
Business Wire
nference Portfolio Company
Becker's Hospital Review
Outsourcing Pharma
Becker's Health IT
The Pharma Letter
Fierce Healthcare
CBS News
nference & Mayo Clinic
STAT News
Mayo Clinic
Medical Design & Outscourcing
JAMA Network
USA Today
Axios
Fast Company
Healthcare Executive
Forbes
FierceBiotech
The Washington Post
The New York Times

nference in the News

All Topics
Article Year
Newest First

November 20, 2026

nference Enters Long-Term Partnership with Cedars-Sinai to Develop AI-Enabled Platform for Advancing Clinical Research and Patient Care

The collaboration will establish a secure AI-enabled platform to help Cedars-Sinai investigators analyze de-identified, multimodal clinical data from over 5 million patients.

PR Newswire

November 18, 2026

nference and Novo partner to advance understanding of cardiometabolic disease and healthy ageing

Collaboration combines clinical trial and real-world insights to increase understanding of cardiometabolic disease

PR Newswire

September 16, 2026

nference Named to TIME’s World’s Top HealthTech Companies for the Second Consecutive Year

nference has been selected as one of TIME’s World’s Top HealthTech Companies of 2026, marking its second consecutive year on the list.

TIME

September 15, 2026

Reuters Covers nference Study on Rising Use of BPC-157, the “Wolverine Peptide”

Reuters highlights nference’s analysis of clinical notes documenting BPC-157 use in 1,039 patients, amid limited evidence of the peptide’s safety and effectiveness.

Reuters

September 2, 2026

nference and Rush University System for Health Launch Long-Term Partnership to Advance AI-Enabled Clinical Research and Patient Care

Partnership will create a real-time, secure, Rush-hosted platform that makes de-identified, multimodal clinical data research-ready to accelerate discovery and improve patient care.

PR Newswire

July 17, 2026

Does stopping a GLP-1 really doom you to regain all the weight?

nference study suggest that some people can keep the weight off.

NBC News

June 9, 2026

Whole-Body Spatial Intelligence Beyond Weight-loss: nference Advances Cardiometabolism Moat for Precision Peptide Medicines and Healthy Longevity

nference announced a series of publications from the Metabolic Agentic Intelligence Atlas initiative, or MAIA, a federated AI program that enables real-time synthesis of biomedical knowledge from the de-identified care patterns of over 30 million patients. The studies provide collectively, for the first-time, a high-resolution precision map of the impact of GLP-1, GIP, and other incretin therapies on the whole human body beyond weight-loss and glucose measurements that have been the primary endpoints of clinical studies thus far.

PR Newswire

April 17, 2026

Lilly’s tirzepatide sheds lean muscle harder than Novo’s semaglutide, study suggests

While Eli Lilly’s tirzepatide helps patients drop more weight than Novo Nordisk’s semaglutide, this might come with greater loss in lean body mass, according to …

Endpoint News

of 10